Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients
1 other identifier
interventional
134
1 country
1
Brief Summary
The impact of tailored patient-provider communication to improve clinical trial recruitment, patient knowledge, and patient engagement will be studied. Tailored patient-provider communication refers to the individualization of patient-provider communication using patients' preferred methods of communication. This involves the utilization of social messaging such as e-mail or text and/or social media platforms. These communication methods purport to and meet individual patient needs whilst ensuring that information is received and in a format that is familiar to each patient. The primary outcomes of the proposed research is to evaluate the impact of tailored patient-provider communication on patient response rates (speed and number), clinical trial recruitment rates, patient knowledge, and patient engagement.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 6, 2020
CompletedStudy Start
First participant enrolled
November 16, 2020
CompletedFirst Posted
Study publicly available on registry
November 18, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 19, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 19, 2022
CompletedDecember 15, 2022
December 1, 2022
11 months
November 6, 2020
December 13, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Patient Response Rates
Patient response rate will determine the first step of patient engagement and assesses a patients willingness to 'interact' with the weblink delivered. Patient response rates will be measured by click rates. Click rates will be calculated using the proportions of patients in both study populations who choose to click on the weblinks delivered throughout the study, regardless of whether or not questionnaires are completed. The time elapsed from when the weblink is sent and when the weblink is clicked will also be recorded.
3 months
Secondary Outcomes (3)
Patient Activation
3 months
Patient Experience
3 months
Patient Drop-out Rate
3 months
Other Outcomes (2)
Potential clinical trial recruitment rate
3 months
Patient Knowledge
3 months
Study Arms (2)
Tailored Delivery of Education
EXPERIMENTALCommunication will be tailored as the mode of weblink delivery will be customized to patient preference.
Non-tailored Delivery of Education
PLACEBO COMPARATORCommunication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy.
Interventions
Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.
Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
Eligibility Criteria
You may qualify if:
- Provide signed and dated informed consent form
- Speak English or Spanish
- Male or female, at least 18 years of age
- Have an active, physician-diagnosed dermatological condition
- Have access to an electronic device that is capable of capturing images with a minimum resolution of 1024x768 pixels
- Have access to at least one form of social messaging (e-mail, SMS, WhatsApp, or Facebook) which can connect online
You may not qualify if:
- Does not have an active dermatological condition at the beginning of the study
- Does not live in southern California
- Unable to fulfill the required tasks of the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Southern Californialead
- National Psoriasis Foundationcollaborator
Study Sites (1)
USC
Los Angeles, California, 90033, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
April Armstrong, MD, MPH
University of Southern California
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, INVESTIGATOR
- Masking Details
- Single-blinded
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor/Professor
Study Record Dates
First Submitted
November 6, 2020
First Posted
November 18, 2020
Study Start
November 16, 2020
Primary Completion
October 19, 2021
Study Completion
January 19, 2022
Last Updated
December 15, 2022
Record last verified: 2022-12
Data Sharing
- IPD Sharing
- Will not share
Subject confidentiality is strictly held in trust by the investigators, study staff, and the sponsor(s) and their agents. The study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor. The study monitor or other authorized representatives of the sponsor may inspect all study documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) for the study subjects. The clinical study site will permit access to such records.